Details

Autor(en) / Beteiligte

• Lee, Joshua D., (M.D., M.Sc.)
• Grossman, Ellie, (M.D. M.P.H.)
• Huben, Laura, (M.P.H.)
• Manseau, Marc, (M.D. M.P.H.)
• McNeely, Jennifer, (M.D. M.Sc.)
• Rotrosen, John, (M.D.)
• Stevens, David, (M.D.)
• Gourevitch, Marc N., (M.D. M.P.H.)

Titel

Extended-release naltrexone plus medical management alcohol treatment in primary care: findings at 15 months

Ist Teil von

• Journal of substance abuse treatment, 2012-12, Vol.43 (4), p.458-462

Ort / Verlag

New York, NY: Elsevier Inc

Erscheinungsjahr

2012

Link zum Volltext

Quelle

Applied Social Sciences Index & Abstracts (ASSIA)

Beschreibungen/Notizen

• Abstract The feasibility of long-term extended-release naltrexone (XR-NTX) alcohol treatment is unknown. Following an initial 12-week, single-arm, observational trial of XR-NTX plus medical management (MM) in primary care, we offered 48 additional weeks of XR-NTX treatment (12 additional monthly injections) in two public primary care clinics as a naturalistic extension study. Of 65 alcohol dependent adults initiating XR-NTX treatment, 40 (62%) completed the initial 12-week XR-NTX observational trial, and 19 (29%) continued treatment for a median of 38 weeks total (range, 16–72 weeks; median 8 total XR-NTX injections). Among active extension phase participants, self-reported rates of drinking days (vs. last 30 days pre-treatment baseline) were low: median 0.2 vs. 6.0 drinks per day; 82 vs. 38% days abstinent; 11 vs. 61% heavy drinking days. Long-term XR-NTX treatment in a primary care MM model was feasible and may promote lasting drinking reductions or alcohol abstinence (clinical trial: NCT00620750 ).